Tekin Meltem, Gökaslan Serkan, Diker Erdem, Aydoğdu Sinan
Ankara Numune Eğitim ve Araştirma Hastanesi Kardiyoloji Kliniği, Ankara.
Turk Kardiyol Dern Ars. 2008 Jan;36(1):35-8.
Little is known about the management of coronary thrombosis in myeloproliferative disease. The occurrence of myocardial infarction in myeloproliferative disease is mostly attributed to coronary thrombosis due to hyperviscosity and thrombocytosis. We presented three cases of acute myocardial infarction associated with polycythemia vera in one patient (male, age 33 years) and essential thrombocytosis in two patients (male, ages 36 and 46 years). None of the patients had diabetes mellitus, hypertension, hyperlipidemia, or a positive family history. One patient with early presentation received thrombolytic therapy, and all the patients were treated with aspirin, beta-blocker, angiotensin 2 receptor blocker, statin, low-molecular-weight heparin, parenteral nitrate, and clopidogrel for acute coronary syndrome, and hydroxyurea for essential thrombocytosis. Control angiographies showed patent coronary arteries in all the cases.
关于骨髓增殖性疾病中冠状动脉血栓形成的管理知之甚少。骨髓增殖性疾病中心肌梗死的发生主要归因于高粘滞血症和血小板增多症导致的冠状动脉血栓形成。我们报告了三例急性心肌梗死病例,其中一例(男性,33岁)与真性红细胞增多症相关,两例(男性,分别为36岁和46岁)与原发性血小板增多症相关。所有患者均无糖尿病、高血压、高脂血症或阳性家族史。一名早期就诊的患者接受了溶栓治疗,所有患者均接受了阿司匹林、β受体阻滞剂、血管紧张素2受体阻滞剂、他汀类药物、低分子量肝素、静脉用硝酸酯类药物和氯吡格雷治疗急性冠状动脉综合征,以及羟基脲治疗原发性血小板增多症。冠状动脉造影复查显示所有病例的冠状动脉均通畅。